Evidence map›Paper›PMID 37664670›Full record

ArticleExperimental and therapeutic medicine2023

Regulation of the stem‑like properties of estrogen receptor‑positive breast cancer cells through NR2E3/NR2C2 signaling.

Shanglun Xie, Yaru Hu, Jiacheng Jin, Lingzhi Fu, Cong Zhang, Qing Yang, Yaxin Niu, Zhiyong Sheng

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shanglun XieSchool of Life Sciences, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China.
Yaru HuDepartment of Ophthalmology, Fuyang People's Hospital, Fuyang, Anhui 236000, P.R. China.
Jiacheng JinSchool of Life Sciences, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China.
Lingzhi FuDepartment of Ophthalmology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233099, P.R. China.
Cong ZhangSchool of Life Sciences, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China.
Qing YangDepartment of Ophthalmology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233099, P.R. China.
Yaxin NiuDepartment of Ophthalmology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233099, P.R. China.
Zhiyong ShengSchool of Life Sciences, Anhui Province Key Laboratory of Translational Cancer Research, Bengbu Medical College, Bengbu, Anhui 233030, P.R. China.
Bengbu Medical College · CNFirst Affiliated Hospital of Bengbu Medical College · CNFuyang Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) are major drivers of metastasis, drug resistance and recurrence in numerous cancers. However, critical factors that can modulate CSC stemness have not been clearly identified. Nuclear receptor subfamily 2 group E member 3 (

Indexed as

estrogen receptor-positive breast cancernuclear receptornuclear receptor subfamily 2 group C member 2nuclear receptor subfamily 2 group E member 3stem-like properties

Identifiers

PMID37664670
PMCPMC10469576
OpenAlexW4386051533

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.